Corporate Finance DEAL Information

May 2009

Informa Plc, England

Value (£M) - 242.0

Informa Plc, London, England, provider of specialist information to academic and scientific, professional, and commercial markets via publishing, events, and performance improvement worldwide, is to launch a deeply discounted rights issue of170,050,097 new ordinary shares to raise GB£242m. Shareholders will be offered two new shares priced at 150p for every five currently held. Further details not disclosed.

----------------------------------------------------------------------------------------------------------------

Morgan Crucible Company Plc, England

Value (£M) - 280.0

Morgan Crucible Company Plc, Windsor, Berkshire, England, manufacturer of carbon and ceramic components for application in a wide range of industries and services, announced the signing of a new 3 year multi-currency facility for GB£280m from a syndicate of eight banks. The new facility replaces the existing US$420m facility which was due to mature in March 2010.

----------------------------------------------------------------------------------------------------------------

Wellbutrin XL, USA

Value (£M) - 288.0

Biovail Laboratories International SRL, a subsidiary of Biovail Corp, Mississauga, Ontario, Canada, a speciality pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialisation of pharmaceutical products utilising advanced drug-delivery technologies, entered into an agreement to acquire the US commercialisation rights to Wellbutrin XL from GlaxoSmithKline Plc, London, England, a developer and manufacturer of vaccines, prescription, and over-the-counter medicines, as well as health-related consumer products. Wellbutrin XL is a bupropion hydrochloride extended-release tablet. Aggregate consideration CA$510m (GB£288.61m).